For the Quarter Ending December 2022
Over the first half of the fourth quarter, Methyldopa price gradually increased at a moderate rate in North America. End-user demand from the pharmaceutical industry kept Methyldopa costs on the sturdy end. Additionally, there was a steep decline in supply chain disruption in the six months leading up to November across several measures, including shipping costs, which further strengthened the Methyldopa market in an upward direction. Prices for Methyldopa stayed on the North side till November when they were recorded at USD 159500 /MT CFR Los Angeles. However, towards the end of q4, they started to fall precipitously due to a major decrease in their offtakes.
In the fourth quarter of 2022, Methyldopa prices in the Asia Pacific area, particularly in China, sharply declined. However, prices remained on the upper side throughout the initial half of q4 due to increased downstream demand balanced with supplies among market participants. On the other hand, the ease in supply chain disruption in November compared to October, including the lower shipping costs, encouraged the traders and suppliers to raise their orders. With the year 2022 concluding, China's production activities started to decline, particularly after November, due to an increase in COVID-19 instances and a reduction in freight costs, supporting the price trend of Methyldopa in China. Overall, the Methyldopa costs noted in the middle of the fourth were assembled at USD 150655/MT FOB Shanghai in China.
The Methyldopa market in Europe followed a similar trajectory to that in Asia Pacific in the fourth quarter of 2022. Due to a rise in demand from the end-user pharmaceutical business, the market trend started off well up until November and reached an assembly price of USD 161850/MT CFR Hamburg in Germany. After December, Methyldopa pricing inquiries from the downstream industry started to decline dramatically, which reinforced the drug's weaker price trend because market participants had plenty of supply and little to no demand. Also, fresher quotations declined in December because of suppliers' high stock levels brought on by the market closure.
For the Quarter Ending September 2022
In the North American region, Methyldopa prices witnessed a stable market sentiment during the third quarter of 2022 due to consistent demand balanced with the supply side from the downstream pharmaceutical sector. Additionally, adequate inventories in the domestic market have noticeably propelled Methyldopa market sentiments to be on the firm side. Also, the zero covid policy in China has abrupted the global supply chain and somewhat supported the price trends of Methyldopa in the United States. Furthermore, towards the termination of Q3, the prices witnessed for Methyldopa went down steadily and were settled at USD 158000/ MT CFR Los Angeles.
During the third quarter of 2022, the pricing trend for Methyldopa in the Asia Pacific showed a stable tendency. Consistent COVID-19 cases and strict lockdown conditions in China during H1 of Q3 kept the market of Methyldopa on the weaker side. Further, weak global demand with soaring energy prices dulled overall trading momentum, affecting the price trends of Methyldopa. Also, owing to fewer purchasing activities, domestic merchants were left with stockpiled products, which compelled them to reduce the prices and destock their lists. With the ending of Q3 2022, the price of Methyldopa witnessed a decremented trend with the settlement of USD 149200/MT FOB Shanghai in China.
In the European region, the prices of Methyldopa witnessed a negative market sentiment backed by the weaker downstream demand and trading activities from the exporting countries. The war between Russia and Ukraine has affected the trading propensity throughout the region, resulting in slowed commodity flow, negatively impacting the price trend for Methyldopa in Europe. Additionally, the providers had sufficient stocks to meet the overall domestic demand. Also, with the ending of Q3, the market witnessed a decremented trend owing to lessening need and halted supplies from the APAC region. The prices recorded at the end of Q3 were settled at USD 160750MT CFR Hamburg.
The North American region witnessed a mixed sentiments in its pricing trend of Methyldopa during the second Quarter of 2022, backed by fluctuation in buying and purchasing activities in the regional market and in downstream demand from end-user enterprises, mainly from the pharmaceutical sector. Moreover, the variable upstream Raw material prices in the second quarter kept the Prixes of Methyldopa affected. Also, the extended port congestion leading to higher freight charges and shortage of cargoes resulted in the price enhancement of Methyldopa API during the end of Q2. Besides, the heightened demand and rerouting in trading activities owing to geopolitical and logistic tension affected the market sentiments. Altogether the prices recorded for Methyldopa were assessed at USD 157150/MT CFR Los Angeles.
During the Second Quarter of 2022, the prices of Methyldopa showcased steady trends in its prices in the APAC region backed by consistent demand in the regional market. Further, rising upstream feed Veratraldehyde prices result in the stably price enhancement of Methyldopa in the market. constant downstream demand resurgence of covid cases and the extended trade disruption witnessed a positive sentiment of Methyldopa in the domestic market. Besides that, toward the end of Q2, the prices for Methyldopa went steady owing to its slight decrease in continual demand. Hence, the market surged in the second quarter with a settlement of USD 149000/MT FOB Shanghai.
The Prices of Methyldopa mimics similar pricing sentiment in the European market as per North America during the Second Quarter of 2022, backed by varying upstream feed Vertraldehyde cost and its unavailability. Furthermore, the steady downstream demand with sufficient stock with the suppliers, kept the prices of Methyldopa stable in the market. Also, an increase in energy and crude oil prices amid Russian-ukraine Geopolitical tension was one factor that resulted in higher Methydopa Cost in the region during themed of Q2. Additionally, the cost of shipping containers and scheduled delays between the APAC-European region also exacerbated Methyldopa prices efficiently in the European region. Towards the termination of q2 the prices went down and were recorded as UASD 165510/MT CFR Hamburg.